Methods for the diagnosis and treatment of t cell-lymphomas ccr8

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sézary cells and showed the expression of CCR8 (CD198) by Sézary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.

Keywords: T-Cell Lymphoma, Diagnostic, Prognosis, CCR8, FACS based approach
Patent Application number: EP21 305 356.4 on 23/03/2021 and PCT/EP2022/057408 on 22/03/2022
Blood Adv 2022 Jun 14 Giustiniani et al. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas doi: 10.1182/bloodadvances.2021006512.

You might also be interested in